<DOC>
	<DOCNO>NCT00005960</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine PSA response , duration PSA response , disease free survival , median survival , overall survival patient chemotherapy naive hormone refractory adenocarcinoma prostate treat doxorubicin cyclophosphamide sequential docetaxel . II . Assess improvement pain time patient treated regimen . OUTLINE : This multicenter study . Patients receive doxorubicin IV 3-5 minute cyclophosphamide IV day 1 , 22 , 43 , 64 , docetaxel IV 1 hour day 85 , 106 , 127 absence disease progression unacceptable toxicity . Patients receive filgrastim ( G-CSF ) subcutaneously daily begin 24 hour completion chemotherapy infusion continue blood count recover . G-CSF must discontinue least 24 hour prior start subsequent chemotherapy infusion . Pain analgesic use assess study , every 3 week study , completion study , 3 month completion study . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter death . PROJECTED ACCRUAL : Approximately 42-105 patient accrue study 18 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma prostate chemotherapy naive refractory hormonal therapy combine androgen blockade No concurrent antiandrogen therapy withdrawal : Must continue antiandrogen therapy completion study OR Must discontinue flutamide least 4 week bicalutamide least 8 week study enrollment , must disease progression antiandrogen therapy , define serial increase PSA ( least 2 measurement take least 2 week apart ) measurable tumor Concurrent LHRH antagonist allow prior orchiectomy No minimum PSA level require Measurable evaluable disease An increase PSA pain without measurable evaluable disease constitute hormone refractory disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % ECOG 02 Life expectancy : At least 6 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : SGOT SGPT great 2 time upper limit normal Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : LVEF normal No impair cardiac status ( e.g. , history severe heart disease , cardiomyopathy , congestive heart failure ) Other : No active infection , define follow : Clinical syndrome consistent viral bacterial infection ( e.g. , influenza , upper respiratory infection , urinary tract infection ) Fever clinical site infection identify Microbiologically documented infection include , limited , bacteremia septicemia HIV negative No malignancy within past 5 year except surgically cure basal cell squamous cell skin cancer No psychiatric , addictive , disorder would preclude informed consent compliance No hypersensitivity E. coli derive protein drug formulate polysorbate 80 ( e.g. , human insulin ) PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent WBC transfusions No concurrent biologic therapy Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : At least 4 week since prior radiotherapy Surgery : See Disease Characteristics Other : No concurrent investigational agent No concurrent acetaminophen fever prophylaxis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>pain</keyword>
</DOC>